SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

(RULE 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)

AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 2)*

Auris Medical Holding AG

(Name of Issuer)

Common shares, nominal value CHF 0.40 per share

(Title of Class of Securities)

H03579101

(CUSIP Number)

Nathalie Auber

Sofinnova Ventures, Inc.

3000 Sand Hill Road, Bldg 4, Suite 250

Menlo Park, CA 94025

(650) 681-8420

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

COPY TO:

Linda Daley, Esq.

c/o Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

1200 Seaport Blvd., Redwood City, CA  94063

(650) 463-5243

February 15, 2017

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

This information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Statement on Schedule 13D

This Amendment No. 2 (“Amendment No. 2”) amends and restates the statement on Schedule 13D initially filed on August 9, 2014 and amended on February 7, 2017 (as amended, the “Original Schedule 13D”) relating to the beneficial ownership of common shares, CHF 0.40 nominal value per share (“Common Shares”), of Auris Medical Holding AG, a Swiss corporation (“Issuer”), filed by and on behalf of Sofinnova Venture Partners VIII, L.P., a Delaware limited partnership (“SVP VIII”), Sofinnova Management VIII, L.L.C., a Delaware limited liability company (“SM VIII”), Dr. Srinivas Akkaraju (“Akkaraju”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), and Dr. Anand Mehra (“Mehra”). Akkaraju is no longer a managing member of SM VIII, and “Reporting Persons” shall mean SVP VIII, SM VIII, Powell, Healy and Mehra, collectively. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. This Amendment No. 2 is being filed to reflect the purchase by SVP VIII of Common Shares and warrants to purchase Common Shares in the February 2017 secondary public offering by the Issuer.

(a)            The class of equity securities to which this statement relates is the Common Shares of the Issuer.

(b)            The Issuer’s principal executive offices are located at Bahnhofstrasse 21, 6300 Zug, Switzerland.

(a)            The persons and entities filing this Schedule 13D are SVP VIII, SM VIII, Powell, Healy, and Mehra. SM VIII, the general partner of SVP VIII, may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by SVP VIII.

(b)            The address of the principal place of business for each of the Reporting Persons is c/o Sofinnova Ventures, 3000 Sand Hill Road, Bldg 4, Suite 250, Menlo Park, California 94025.

(c)            The principal occupation of each of the Reporting Persons is the venture capital investment business. The principal business of SVP VIII is to make investments in private and public companies, and the principal business of SM VIII is to serve as the general partner of SVP VIII. Powell, Healy and Mehra are the managing members of SM VIII.

(d)            During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)            During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)            SVP VIII is a Delaware limited partnership. SM VIII is a Delaware limited liability company. Powell, Healy, and Mehra are U.S. citizens.

On November 26, 2013, Healy was granted a stock option from the Issuer to purchase 6,250 Common Shares at an exercise price of CHF 5.28 per share. Such option will vest on November 25, 2017 and will become exercisable upon vesting. Such option will expire on November 25, 2019.

On December 9, 2013, SVP VIII entered into a non-interest bearing convertible loan with the Issuer with a principal amount of CHF 7,020,024. On January 13, 2014, SVP VIII exercised its conversion option on such loan, and the loan amount was converted into 1,329,550 Series C preferred shares of the Issuer.

On April 5, 2013, SVP VIII entered into a Series C investment agreement pursuant to which SVP VIII acquired from the Issuer an aggregate 2,363,625 shares of Series C preferred shares for a purchase price of CHF 5.28 per share, or CHF 12,479,940 in the aggregate.

In connection with the closing of the Issuer’s initial public offering of Common Shares (“IPO Offering”), the Series C preferred shares automatically converted on a one-for-one basis on August 11, 2014 into 3,693,175 Common Shares.

On August 11, 2014, SVP VIII purchased 2,125,000 Common Shares at $6.00 per share in the IPO Offering, or $12,750,000 in the aggregate. Such purchase occurred pursuant to and on the terms set forth in the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) on August 7, 2013 with the Securities and Exchange Commission (the “IPO Prospectus”).

The Issuer effected a 25:1 forward stock split on December 27, 2013. Accordingly, unless otherwise noted above, all disclosed numbers and nominal value of shares are adjusted for such stock split.

On December 29, 2014, Healy was granted a stock option from the Issuer to purchase 7,815 Common Shares at an exercise price of $4.05 per share. On December 29, 2016, 50% of the Common Shares subject to the option vested and became exercisable. The remaining Common Shares subject to the option will vest and become exercisable on December 29, 2017. The option expires on December 29, 2022.

On September 15, 2015, Healy was granted a stock option from the Issuer to purchase 10,000 Common Shares at an exercise price of $4.68 per share. The option vested and became exercisable on September 15, 2016. The option expires on September 15, 2023.

On April 30, 2016, Healy was granted a stock option from the Issuer to purchase 5,000 Common Shares at an exercise price of $3.92 per share. The option will vest and become exercisable on April 30, 2017. The option expires on April 30, 2024.

In February 2017, the Issuer held a public offering (the “Secondary Offering”) of Common Shares and warrants, with each warrant entitling the holder to purchase 0.70 of a Common Share at an exercise price of $1.20 per whole Common Share. The Common Shares and warrants were sold in units (each a “Unit”), with each Unit consisting of one Common Share and one warrant. Each Unit was sold at a price of $1.00 per Unit. The Common Shares and warrants will be mandatorily separable immediately upon issuance. The warrants will become exercisable upon issuance, and will expire five years after issuance.

On February 15, 2017, in connection with the Secondary Offering, SVP VIII purchased 2,000,000 Units from the Issuer at $1.00 per Unit, or $2,000,000 in the aggregate. Such purchase occurred pursuant to and on the terms set forth in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) on February 16, 2017 with the Securities and Exchange Commission (the “Secondary Prospectus”).

The source of the funds for all purchases and acquisitions by the Reporting Persons was from working capital.

No part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.

The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Shares and/or retain and/or sell all or a portion of the Common Shares held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Shares held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, among other things, the price levels of the Common Shares, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

(a,b)         Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 44,329,704 Common Shares outstanding following the Secondary Offering as reported by Issuer in the Secondary Prospectus.

(c)            Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the Common Shares of the Issuer during the past 60 days.

(d)            Under certain circumstances set forth in the limited partnership agreement of SVP VIII, the general partner and limited partners of SVP VIII may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

(e)            Not applicable.

Pursuant to a Lock-Up Agreement, dated June 27, 2014, entered into with Jefferies LLC and Leerink Partners LLC in connection with the IPO Offering, the Reporting Persons are subject to a Lock-Up Period (as defined in the Lock-Up Agreement) commencing on June 27, 2014 and continuing and including the date 180 days after the date of the IPO Prospectus, during which the Reporting Persons have agreed, subject to limited exceptions, not to offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any Common Shares or securities convertible into or exchangeable or exercisable for any Common Shares, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares.

The Reporting Persons are party to a Registration Rights Agreement among the Issuer, the Reporting Persons and other shareholders, dated August 11, 2014 (the “Registration Rights Agreement”). Subject to the terms of the Registration Rights Agreement, holders of Common Shares having registration rights can demand that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The form of Registration Rights Agreement described in Item 6, filed on July 21, 2014 as Exhibit 4.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form F-1 (File No. 333-197105), and is incorporated herein by reference.

On November 26, 2013, Healy was granted a stock option from the Issuer to purchase 6,250 Common Shares at an exercise price of CHF 5.28 per share. Such option will vest on November 25, 2017 and will become exercisable upon vesting. Such option will expire on November 25, 2019. On December 29, 2014, Healy was granted a stock option from the Issuer to purchase 7,815 Common Shares at an exercise price of $4.05 per share. 50% of the shares subject to the option vested on December 29, 2016 and became exercisable upon vesting. The remaining shares will vest on December 29, 2017 and will become exercisable upon vesting. Such option will expire on December 29, 2022. On September 15, 2015, Healy was granted a stock option from the Issuer to purchase 10,000 Common Shares at an exercise price of $4.68 per share. Such option vested on September 15, 2016 and became exercisable upon vesting. Such option will expire on September 15, 2023. On April 30, 2016, Healy was granted a stock option from the Issuer to purchase 5,000 Common Shares at an exercise price of $3.92 per share. Such option will vest on April 30, 2017 and will become exercisable upon vesting. Such option will expire on April 30, 2024. The Issuer’s Stock Option Plan C is more fully described in the IPO Prospectus and incorporated herein by reference.

With respect to the warrants purchased by SVP VIII in the Secondary Offering, the form of warrant is filed as Exhibit 4.1 to the Form 6-K (File Number 001-36582) filed by the Issuer on February 21, 2017 and is incorporated herein by reference.

Pursuant to a Lock-Up Agreement, certain Reporting Persons have agreed, subject to certain exceptions, not to sell or transfer any Common Shares or securities convertible into or exchangeable or exercisable for Common Shares, for 60 days after the date of the Secondary Prospectus, in each case, without first obtaining the written consent of Roth Capital Markets, LLC. The Form of Lock-Up Agreement is filed as Exhibit A to the Underwriting Agreement filed on February 21, 2017 as Exhibit 1.1 to the Form 6-K (File Number 001-36582) filed by the Issuer and is incorporated herein by reference.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  March 8, 2017